The Food and Drug Administration (FDA), the regulatory agency of the United States, approved this Saturday (27) the emergency use Johnson & Johnson vaccine against Covid-19.
Janssen, which is what the vaccine is called, was the third to be approved by the agency, which is a kind of American Anvisa.
The Janssen vaccine's main differentials is the fact that it is applied in a single dose, in addition to being able to be stored in common refrigerators. In addition to it, the FDA has also authorized the use of Pfizer / BioNTech and Modern.
In note, the agency said the clinical tests showed that the Johnson & Johnson vaccine did not present any relevant safety problems in phase 3 clinical trials and can be administered to anyone over the age of 18.
The level of effectiveness was 66,9% against mild and severe cases in tests performed in the United States, in studies conducted in South Africa, the degree of efficiency was slightly lower, which may indicate that the vaccine is less effective against South African variant Covid-19.
Vaccine is the first adenovirus approved in the US
Janssen is the first vaccine that uses adenovirus technology to gain FDA approval to be applied in the United States. Those that were approved before it use another technology, that of RNA.
In practice, the Johnson & Johnson immunizer uses a harmless virus, which receives a part of the Sars-Cov-2 gene and delivers it to the body's defense cells. With this, they learn to recognize it and are able to fight it when exposed to the virus itself.
On paper, Janssen is the vaccine with the lowest efficacy rate among those approved by the FDA, with Pfizer / BioNTech having 95% efficiency and Moderna having 94,1% in phase 3 clinical studies.
But factors such as the population that participated in the phase 3 tests and the variants in circulation at the time the studies were carried out can change these numbers. But the most important thing is the reduction in the number of hospitalized and killed by Covid-19, something that Janseen should help to achieve.
"What matters to you are hospitalizations and deaths," said Ashish Jha, dean of Brown University School of Public Health, in a statement. interview with NPR. "And Johnson & Johnson seems to be just as good as Moderna and Pfizer in preventing this."
Street: The Verge
Have you watched our new videos on YouTube? Subscribe to our channel!